Get the Stockscreener App
24.39
6.79%
1.55
After Hours:
24.50
0.11
+0.45%
Rigel Pharmaceuticals stock is traded at $24.39, with a volume of 1.00M.
It is up +6.79% in the last 24 hours and up +46.93% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$22.84
Open:
$23.3
24h Volume:
1.00M
Relative Volume:
3.48
Market Cap:
$429.63M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-174.21
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+7.92%
1M Performance:
+46.93%
6M Performance:
+161.41%
1Y Performance:
+99.92%
1-Day Range:
$23.10
$24.48
1-Week Range:
$20.37
$24.48
52-Week Range:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
24.39 | 429.63M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock - Investing.com India
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 - Investing.com India
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock - Investing.com India
CEO, President Rodriguez Raul R sold $200,075 worth of shares (9,352 units at $21.39), decreasing direct ownership by 4% to 239,454 units (SEC Form 4) - Quantisnow
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38% - Simply Wall St
BlackRock, Inc. Expands Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Down 43.4% in January - MarketBeat
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? - MSN
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Average Target Price from Analysts - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Consensus PT from Brokerages - Defense World
When (RIGL) Moves Investors should Listen - Stock Traders Daily
JPMorgan Chase & Co. Purchases 8,140 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 - Marketscreener.com
Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: diverse portfolio fuels growth, stock faces headwinds - Investing.com Australia
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment - MSN
Rigel enrols first subject in Phase I sickle cell disease therapy trial - Clinical Trials Arena
Cantor Fitzgerald Estimates RIGL FY2025 Earnings - Defense World
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Marketscreener.com
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment By Investing.com - Investing.com Australia
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib - TipRanks
Equities Analysts Offer Predictions for RIGL FY2025 Earnings - MarketBeat
JW Pharmaceutical gains approval for immune thrombocytopenia treatment TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Long Term Trading Analysis for (RIGL) - Stock Traders Daily
KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel PharmaceuticalsCHOSUNBIZ - 조선비즈
Assenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals Shares Preliminary Financial Results in Recent 8-K Filing - Defense World
Barclays PLC Has $442,000 Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Barclays PLC Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Short Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1% - MarketBeat
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
HC Wainwright Brokers Raise Earnings Estimates for RIGL - Defense World
Rigel (RIGL) Upgraded to Buy: Here's Why - MSN
Equities Analysts Set Expectations for RIGL Q4 Earnings - MarketBeat
Research Analysts Issue Forecasts for RIGL FY2024 Earnings - Defense World
Rigel Pharmaceuticals Seeks for Acquisitions -January 16, 2025 at 11:15 am EST - Marketscreener.com
Cantor Fitzgerald Has Positive View of RIGL FY2024 Earnings - MarketBeat
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Dru - Asianet Newsable
Rigel forecasts revenue growth in 2025, reports Q4 sales - Investing.com India
RIGLRigel Pharmaceuticals Inc. (New) Latest Stock News & Market Updates - StockTitan
Rigel Pharmaceuticals sets 2025 sales outlook above estimates - MSN
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):